. Ueda A, Hosokawa A, Ogawa K, et al. Non-parison between irinotecan plus mitomycin C and irinotecan alone in patients with advanced gastric cancer refractory to fluoropyrimidine and platinum. Anticancer Res. 2013;33:5107–5111.Р23. Kim JY, Ryoo HM, Bae SH, et al. Multi-center randomized phase II study of weekly docetaxel versus weekly docetaxel-plus-oxaliplatin as a second-line chemotherapy for patients with advanced gastric cancer. Anticancer Res. 2015;35:3531–3536.Р24. Lorenzen S, Riera Knorrenschild J, Haag GM, et al. Lapatinib versus lapatinib plus capecitabine as second-line treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-oesophageal cancer: a randomised phase II trial of the Arbeitsgemeinschaft Internistische Onkologie. Eur J Cancer. 2015;51:569–576.
全文预览
